
Home
Chapter Home
Jobs
Conferences
Fellowships
Books
Advertisement
Breast malignant, males, children
Carcinoma subtypes
BRCA2 associated breast carcinoma
Reviewer: Monika Roychowdhury, M.D. (see Reviewers
page)
Revised: 15 November 2012, last major update April 2012
Copyright: (c) 2001-2012, PathologyOutlines.com, Inc.
Definition
=========================================================================
● BRCA2 associated breast cancer is not part of WHO breast classification
● BRCA2 is a tumor suppressor gene at 13q12-13 (OMIM 600185)
● See also Stains chapter
Epidemiology
=========================================================================
● 12% of women referred for genetic testing have BRCA1/BRCA2 deleterious mutations, rate is similar among different ancestries (Cancer 2009;115:2222), but higher in Ashkenazi Jewish women
● Manchester scoring system assesses individual risk of BRCA1/2 mutations (J Med Genet 2009;46:811)
● 60-75% with germline mutations get breast cancer by age 70, 88% at age 80
(BMC Cancer 2008;8:155), but usually by age 50
● Patients also have higher risk of cancers of ovary (39-63%), bone, pharynx, prostate, pancreas
(J Med Genet 2005;42:711); also other organs
● Slightly more frequent in black (2.6%) versus white (2.1%) American patients (Cancer Res 2006;66:8297)
● For patients with 10% or lower risk of BRCA1/2 mutation, genetic screening is not cost effective (Value Health 2009;12:207)
Case reports
=========================================================================
● Invasive cancer 33 years after prophylactic bilateral subcutaneous mastectomies
(World J Surg Oncol 2005;3:52)
Micro description
=========================================================================
● Usually invasive ductal carcinoma, no special type
● High grade features and pushing tumor margin (Am J Surg Pathol 2007;31:121)
● High incidence of DCIS (Cancer Prev Res (Phila Pa) 2009;2:122)
Micro images
=========================================================================
Typical histological patterns
Various immunostains
Positive stains
=========================================================================
● ER; usually luminal phenotype (ER+, HER2-)
● bcl1/cyclinD1
(Mod Pathol 2008;21:1262)
Negative stains
=========================================================================
● CK5 (usually), HER2 (usually)
Additional references
=========================================================================
● Arch Pathol Lab Med 1999;123:1023, Wikipedia, National Cancer Institute
End of Breast malignant, males, children > Carcinoma subtypes > BRCA2 associated breast carcinoma
This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patient's clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician.
All information on this website is protected by copyright of PathologyOutlines.com, Inc. Information from third parties may also be protected by copyright. Please contact us at copyrightPathOut@gmail.com
with any questions (click here for other
contact information).